The issue of pricing is a familiar discussion for the pharma industry and Ruchin Kansal, of Virtusa, believes that there is the potential for a win-win situation.
Gilead says launching generic versions of its pricey hepatitis C drugs more than a decade prior to patent expiries will more closely align product list prices with their cost.
GSK has invested $27.8m into manufacturing operations in Canada, including a technology transfer of Voltaren products from facilities in Switzerland to Mississauga.
MannKind Corporation, of Afrezza fame, and United Therapeutics have signed an exclusive licensing and collaboration agreement for dry powder pulmonary hypertension products.
As Novartis looks to sell a major chunk of its generics portfolio in the US, in-PharmaTechnologist has a look back at some of the stories this year that have signposted larger, on-going trends in the US generics market.
In Novartis’ latest restructuring move for 2018, the pharma giant announced plans to sell US generic oral solids and dermatology businesses to Aurobindo Pharma US.
Chongqing FDA has published an open letter, apparently from an employee of Fosun Pharma, stating that the firm has fabricated a “large number” of production reports.
Tjoapack and Veratrak partnered to establish the use of blockchain technology across the pharmaceutical industry for the first time in a GxP environment.
